Blog

This is tagline here

Begbroke Science Park > News and Press > Prosensa Initiates First Patient Dosing in Phase I/II trial of PRO053
Please set your featured image

Prosensa Initiates First Patient Dosing in Phase I/II trial of PRO053

Prosensa

Prosensa Holding N.V. (NASDAQ: RNA), the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, today announced the dosing of the first patient in its Phase I/II clinical trial of PRO053, an exon-skipping compound for the treatment of Duchenne muscular dystrophy (DMD).

To read more please click here

Ben Roeves